drugset / Trial / NCT00049530
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase 2
Completed
32 enrolled
Eastern Cooperative Oncology Group
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage IV melanoma.
Timeline
- Start
- 2004-01-13
- Primary completion
- 2012-08
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | — | Subcutaneous |